Avaliação do uso de Rheumazin®, uma associação do piroxicam, dexametasona, cianocobalamina e orfenadrina na exodontia do terceiro molar

Abstract

Third molar extraction is a common procedure with pain frequently moderate or severe in intensity, and with sufficient numbers of patients to make studies relatively easy to perform. The aim of this study was to determine the efficacy and the safety of the therapeutic combination of piroxicam, dexamethasone, orphenadrine citrate and cyanocobalamin (Rheumazin®) in comparison to piroxicam alone (Feldene®) in a mandibular third molar surgery model. Eighty patients selected for removal of the third molar were included in this study which was randomized and double blind. They received Rheumazin or Feldene po 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated using a tape measuring method. Record of adverse effects and patient’s satisfaction was also considered. Although the results showed that there was no statistically significant difference in facial swelling between the two groups, Rheumazin® reduced pain at 6th and 120th h of treatment. Rheumazin® also demonstrated a better safety profile preventing adverse effects including nausea, indisposition and epigastric pain, among others, when compared to Feldene®. This fact makes Rheumazin® a good choice for post-surgery treatment in third molar removal